-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III

Symposia: Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms Program: Oral and Poster Abstracts
Type: Poster
Monday, December 9, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)

Gregory Crimmins, PhD1*, Min Wu, PhD2*, Francis Roushar, PhD2*, Claudia F. Ramos Aguilar, BS2*, Mehdi Gharghabi, PharmD3*, Banumathi Cole, PhD2*, Rosa Lapalombella, PhD3 and Dennise A. De Jesús-Díaz, PhD2*

1Remedy Plan Therapeutics, GAITHERSBURG, MD
2Remedy Plan Therapeutics, Gaithersburg, MD
3The Ohio State University, Columbus, OH

Bing Li, MD1,2*, Qing-song Yin3*, Xiaojing Yan, MD, PhD4, Min Hang5*, Hai-Jun Guo5*, Sheng Wang5*, Yi-wei Wang5*, Yong-jiang Hei5* and Zhi-jian Xiao1,2*

1MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China
3Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
4Department of Hematology, The First Hospital of China Medical University, Liaoning, China
5Biocity Biopharmaceutics Co. Ltd, Wuxi, China

Donia M. Moujalled, PhD1,2*, Giovanna Pomilio1,2*, Thomas Morley1,2*, Veronique Litalien1,2*, Natasha S. Anstee, PhD2,3*, Sun Loo, MBBS2,3,4, Zhi-Han Yeoh, MBBS1,2,4*, Clovis Boibessot, PhD5*, Laura Bresson, PhD5*, Ana-Leticia Maragno, PhD5*, Caroline Liot, PharmD, PhD5* and Andrew H Wei, MBBS, PhD, FRACP, FRCPA3,6,7

1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
2Department of Medical Biology, The University of Melbourne, Melbourne, Australia
3The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
4Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia
5Oncology Research and Development Unit, Institut de Recherches Servier, Gif-sur-Yvette, France
6Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia
7The University of Melbourne, Melbourne, VIC, Australia

Gowri Poigaialwar, PhD1*, Sumiko Takao, MD, PhD2,3, Sovira Chaudhry, MSc4*, Laura K. Schmalbrock, MD2,3*, Varun Gupta, PhD1*, Alex Kentsis, MD, PhD2,3,5,6, Julio A. Aguirre-Ghiso, PhD7*, Marina Konopleva8, Maria S. Sosa, PhD9* and Anna Skwarska, PhD4

1Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, New York, NY
2Tow Center for Developmental Oncology, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
3Molecular Pharmacology Program, Sloan Kettering Institute, New York, NY
4Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY
5Departments of Pediatrics, Pharmacology and Physiology & Biophysics, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY
6Memorial Sloan-Kettering Cancer Center, New York, NY
7Department of Cell Biology, Cancer Dormancy Institute, Montefiore Einstein Comprehensive Cancer Center, Gruss-Lipper Biophotonics Center, Albert Einstein College of Medicine, New York, NY
8Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY
9Department of Microbiology and Immunology, Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Cancer Dormancy Institute, Albert Einstein College of Medicine, New York, NY

Yun Huang, MD, PhD1*, Xuejie Jiang, M.D.2* and Zhiquan Long1*

1Nanfang Hospital, Southern Medical University, Guangzhou, China
2Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

Jyoti Kandarp1*, Arnold Kloos1*, Kerstin Goerlich1*, Nadine Kattre1*, Thomas Plenge1* and Michael Heuser, MD1,2

1Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany
2Department of Internal Medicine IV, University Hospital Halle (Saale), Halle (Saale), Germany

Gang Huang, PhD1,2, Jie Bai1*, Mingzhe Pan1*, Dong Liu, PhD3*, Min Xiong3* and Shaojiang Deng, PhD3*

1Department of Cell Systems and Anatomy, UT Health San Antonio, San Antonio, TX
2Department of Pathology and Laboratory Medicine, UT Health San Antonio, San Antonio, TX
3Kind Pharmaceuticals, LLC, Redwood City, CA

Norman Lu1*, Patricia Soulard1*, Ibrahim Kay1*, Kai Li1*, Xiubin Gu1*, Heather Sadlish1*, Jay Lee1*, Mariam Elhawary1*, Michael Rotelli1*, Sam Hasson1*, Thomas Wynn1*, Chris Yates1*, Zhiping Weng2*, Simon Xi1* and Travis Wager, PhD1*

1Rgenta Therapeutics, Woburn, MA
2University of Massachusetts Medical School, Worcester, MA

Carmen Jimenez1*, Sophie Peng2*, Rama Krishna Narla2*, Joshua Baughman3*, Scott Wood2*, Jean Lu4*, Noelia Purroy5*, Gina Yanochko6*, Mark Nagy7*, Gang Lu4*, Mark Rolfe2, Daniel W. Pierce8* and Soraya Carrancio, PhD2*

1Bristol Myers Squibb, Seville, CA
2Research and Development, Bristol Myers Squibb, San Diego, CA
3Bristol-Myers Squibb, San Diego, CA
4GluBio Therapeutics, San Diego, CA
5Bristol Myers Squibb, San Francisco, CA
6Janssen Research & Development, San Francisco, CA
7Treeline Biosciences, Fairfax, VA
8Research and Development, Bristol Myers Squibb, Brisbane, CA

Nanni Schmitt1*, Jana-Julia Siegler2*, Alexandra Beck1*, Lea Hoppe1*, Mohammed Abba, MD1*, Alexander Streuer, MD1*, Stefan Klein, MD1, Wolf-Karsten Hofmann, MD1, Christian Merz2*, Jens Pahl2* and Daniel Nowak, MD1*

1Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
2Affimed GmbH, Mannheim, Germany

Orsola Di Martino, PhD1,2, Mary Basse1*, Nancy BJ Arthur, PhD3, Nishanth Gabriel, PhD1*, Judith Sokei, BPharm, MSc1, Ahmed Mahmoud, MD3*, Marco Vitale, MD4*, Elena Masselli, MD2*, Cecilia Carubbi, PhD2*, Stephen Sykes, PhD5 and Francesca Ferraro, MD, PhD6

1Department of Pediatrics, Division of Hematology-Oncology, Washington University of Saint Louis, School of Medicine, Saint Louis
2Department of Medicine and Surgery, University of Parma, Parma, Italy
3Department of Internal Medicine, Division of Oncology, Washington University of Saint Louis, School of Medicine, Saint Louis
4Vita-Salute University IRCSS San Raffaele, Milano, ITA
5Department of Pediatrics, Washington University School of Medicine, St Louis, MO
6Department of Internal Medicine, Division of Oncology, Washington University of Saint Louis, School of Medicine, SAINT LOUIS, MO

Chan Yang1*, Qinglong Guo2*, Hui Hui2*, Hui Li2*, Chunhua Song, M.D., Ph.D.3 and Zheng Ge, MD, PhD1

1Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Institute of Hematology Southeast University, Nanjing, China
2State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
3The Ohio State University, Columbus, OH

Junichiro Yuda, MD, PhD1, Takahiko Aramaki, PhD2*, Haruka Matsumura2*, Kanto Nakajima, PhD2* and Motoya Mie, PhD2*

1Department of Hematology and Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa-Shi, Chiba, Japan
2Kawasaki Research Laboratories, BrightPath Biotherapeutics Co.,Ltd., Kawasaki, Japan

Nathalie Javidi-Sharifi, MD, PhD1, Jeremy Zhang2*, Sandra Wiley, PhD, MSc3, Richard G Ghalie, MD, MBA3, Alexey V. Danilov, MD, PhD4 and Matthew S. Davids, MD, MMSc5

1Dana-Farber Cancer Institute, Boston
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
3MEI Pharma, San Diego, CA
4City of Hope National Medical Center, La Canada Flintridge, CA
5Dana-Farber Cancer Institute, Boston, MA

Yohei Yasuda, MD1*, Yuta Fukui, MD2*, Ken Morita, MD, PhD2*, Muzhapaer Mubalizi, PhD3*, Hiroki Hayashida, MD, PhD2*, Toshiya Hino2*, Yosuke Masamoto, MD, PhD3,4 and Mineo Kurokawa, MD, PhD2,4

1Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Bunkyo-Ku, TKY, Japan
2Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
3Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, JPN
4Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, Tokyo, Japan

Masahiro Uni, MD, PhD1,2, Asher Preska Steinberg, PhD2,3*, Alicia Slavit1,2*, Sophia Rha1,2*, Shuyuan Cheng1,2, Laura K. Schmalbrock, MD1,2*, Jiayu Su4,5,6*, Jing Ma, PhD7*, Andrew McPherson, PhD3*, Charles G. Mullighan, MBBS, MSc, MD7, Torsten Haferlach, MD8, Ilaria Iacobucci, PhD9, Jeffery M Klco, MD, PhD7, Raul Rabadan, PhD4,5,10* and Alex Kentsis, MD, PhD1,2,11

1Molecular Pharmacology Program, Sloan Kettering Institute, New York, NY
2Tow Center for Developmental Oncology, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
3Halvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
4Program for Mathematical Genomics, Columbia University, New York, NY
5Department of Systems Biology, Columbia University, New York, NY
6New York Genome Center, New York, NY
7Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
8MLL Munich Leukemia Laboratory, Munich, Germany
9St. Jude Children's Research Hospital, Memphis, TN
10Department of Biomedical Informatics, Columbia University, New York, NY
11Departments of Pediatrics, Pharmacology and Physiology & Biophysics, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY

Zhou Yu, PhD1*, Zhiyan Liang, PhD2*, Xinyi Yao, BS1*, Yanqiu Ji, BS1*, Dajun Yang, MD, PhD1,2,3* and Yifan Zhai, MD, PhD1,2,4

1Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China
2Ascentage Pharma Group Inc., Rockville, MD
3Department of Experimental Research, State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
4Guangzhou Healthquest Pharma Co., Ltd., Guangzhou, China

Josephine Dubois1*, Kai Wu2*, Darren King3*, Xianing Zheng1*, Qianyi Ma1*, Karan Bedi1*, Jun Li1* and Sami N. Malek, MD4

1University of Michigan, Ann Arbor
2UCSF, San Francisco
3Rogel Cancer Center, University of Michigan, Ann Arbor, MI
4Department of Medicine, University of Michigan Medical School, Ann Arbor, MI

Sophie C James1*, Samantha Atkinson2,3*, Richard Burt, PhD, FRCPath, MRCP2,3,4*, Cristina Lo Celso5* and Paolo Gallipoli, MD/PhD1

1Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
2The Francis Crick Institute, London, United Kingdom
3Imperial College London, London, United Kingdom
4University College London Hospitals, London, United Kingdom
5Imperial College of London, London, United Kingdom

Changqing Jiao1*, Chen Hu2*, Mengya Pan1*, Junjie Zhou1*, Qingsong Liu2* and Jian Ge1*

1Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
2Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, China

Xiaorong Gu, PhD1*, Yahan Zhang, MS2, Songa Bae1*, Dongxu Jiang, PhD2, Daniel Vail, PhD2*, Simon Schlanger, MS2*, Jaroslaw Maciejewski1 and Babal K. Jha, PhD1,2

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Center for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH

Bing Z. Carter, PhD1, Po Yee Mak1*, Baozhen Ke, BS1*, Xiaogang Wu2*, Steffen Boettcher, MD3*, Lauren B. Ostermann, BSc1*, Andrea Bedoy1*, Georgina Gener-Ricos, MD4*, Jayastu Senapati, MD, DM, MBBS4, Courtney D. DiNardo, MD, MSc5, Anna Puzio-Kuter6*, Arnold Levine7* and Michael Andreeff, MD, PhD1

1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Zurich, Switzerland
4Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
6PMV Pharmaceuticals, Inc, Princeton, NJ
7Institute for Advanced Studies, Princeton

Sonali P Barwe, PhD, MSc1, Neha Bhagwat, PhD2 and Anilkumar Gopalakrishnapillai, PhD, MSc3

1Nemours Children's Hospital, Wilmington, DE
2Prelude Therapeutics Incorporated, Wilmington, DE
3Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, Nemours Children's Hospital, Wilmington, DE

Nataly Cruz-Rodriguez, PhD1, Hua Tang, PhD2*, Milad Rouhimoghadam, PhD1*, Junzhuo Liao, PhD2*, Benjamin Bateman1*, Briana Bates, MS1*, Mario Pinzas1*, Xuhui Huang, PhD2*, Weiping Tang, PhD2* and Michael W. Deininger, MD, PhD1,3

1Versiti Blood Research Institute, Milwaukee, WI
2University of Wisconsin-Madison, Madison, WI
3Medical College of Wisconsin, Milwaukee, WI

Man Li1,2*, Jingjie Dong3*, Yaonan Hong3*, Li Jin2*, Chengtao Sun2*, Qi Liu3*, Liqin Li2*, Xiaoxiao Han2*, Shengqian Deng2*, Yue Feng2*, Yiping Shen4*, Guoyin Kai2* and Dijiong Wu, MD, PhD4

1Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
2Zhejiang Key TCM Laboratory for Chinese Resource Innovation and Transformation, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China
3The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
4Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China

Xiaorong Gu, PhD1*, Songa Bae1*, Yahan Zhang, MS2, Nakisha D Williams, MBBS1*, Dongxu Jiang, PhD2, Simon Schlanger, MS2*, Valeria Visconte, PhD3, Jaroslaw Maciejewski1 and Babal K. Jha, PhD1,2

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Center for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Taussig Cancer Institute, Cleveland, OH

Sohani K Sandhu1*, Julia G Kim2*, Ritesh V Dontula2*, Joshua J Cooper2*, Jaden A Sherman2*, Max P Rochette2*, Lana E Kim1*, Michele S. Redell, MD1 and Alexandra McLean Stevens, MD3

1Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX
2Baylor College of Medicine / Texas Children's Hospital, Houston, TX
3Baylor College of Medicine/ Texas Children's Hospital, Bellaire, TX

Luke Jones, PhD1,2, Oleksii Rukhlenko, PhD1,2*, Tânia Dias1,2*, Ciardha Carmody1,2,3*, Kieran Wynne2*, Boris Kholodenko, PhD1,2* and Jonathan Bond, MD, PhD1,2,4*

1School of Medicine, University College Dublin, Dublin, Ireland
2Systems Biology Ireland, Dublin, Ireland
3SFI Centre for Research Training in Genomics Data Science, Dublin, Ireland
4Children's Health Ireland at Crumlin, Dublin, Ireland

Daniel Neville1*, Daniel Ferguson, PhD1*, Emily Heikamp, MD, PhD2, Charles Bell, PhD3*, Scott A Armstrong, MD, PhD4 and Omer Gilan5*

1Monash University, Clayton, VIC, Australia
2Dana Farber Cancer institute, Boston, MA
3University of Queensland, Brisbane, Australia
4Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
5Australian Centre for Blood Diseases, Monash University, Coburg, VIC, Australia

*signifies non-member of ASH